Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teijin's Novel Gout Drug To Launch In Europe

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Teijin Pharma will launch xanthine oxidase inhibitor TMX67, its novel gout drug, in Europe, the company announced Feb. 25.The Tokyo-based company received a positive recommendation Feb. 21 from the European Medicines Agency's Committee for Medicinal Products for Human Use
Advertisement

Related Content

Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review
Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review
Takeda’s Febuxostat Finally Gets Advisory Panel Review
Takeda’s Febuxostat Finally Gets Advisory Panel Review
Advertisement
UsernamePublicRestriction

Register

SC068141

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel